Osaka Metropolitan University Hospital is a university hospital in Japan. It's located in Abeno-ku, Osaka, and affiliated with Osaka Metropolitan University.

There are 980 beds in Osaka Metropolitan University Hospital.

During the past decade, Osaka Metropolitan University Hospital conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 4 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 4 clinical trials were completed. i.e. 11.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka Metropolitan University Hospital" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Amgen" with 4 trials sponsored, "Pfizer" with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Eli Lilly and Company" with 3 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka Metropolitan University Hospital" #1 collaborator was "Amgen Astellas Biopharma K.K." with 1 trials as a collaborator, "Chugai" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Osaka Metropolitan University Hospital" are "Multiple Myeloma" (3 trials), "Ulcerative Colitis" (3 trials), "Carcinoma, Hepatocellular" (2 trials), "Hypertension, Portal" (2 trials) and "Mucopolysaccharidosis I" (2 trials). Many other conditions were trialed in "Osaka Metropolitan University Hospital" in a lesser frequency.

Most popular intervention types in "Osaka Metropolitan University Hospital" are "Drug" (39 trials), "Other" (6 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Rituximab" (4 trials), "Atezolizumab" (3 trials), "Dexamethasone" (3 trials) and "Faricimab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Osaka Metropolitan University Hospital" are 38 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Osaka Metropolitan University Hospital". undefined are not yet recruiting, 18 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Osaka Metropolitan University Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Osaka Metropolitan University Hospital, 4 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".